Literature DB >> 6696534

Hemodynamic effects of vasopressin, alone and in combination with nitroprusside, in patients with liver cirrhosis and portal hypertension.

P Mols, R Hallemans, M Van Kuyk, C Melot, P Lejeune, H Ham, F Vertongen, R Naeije.   

Abstract

We have investigated the effects on systemic, pulmonary, hepatic, and renal hemodynamics, and on blood gases of vasopressin, 0.4 U/min I.V. first alone, then in combination with nitroprusside 1-5 micrograms/kg/min I.V., in 12 patients with liver cirrhosis and portal hypertension. Portal pressures were estimated by the gradient between occluded and free hepatic vein pressures, hepatic blood flow was measured by indocyanine green infusion, renal blood flow by an isotopic method, and cardiac output by thermodilution. Vasopressin alone reduced cardiac output (-23%) and O2 delivery to the tissues (-25%), increased mean arterial pressure (+20%) and filling pressures of the heart (+136%), reduced portal pressures (-36%) (from 19 +/- 1 to 12 +/- 1 mmHg, mean +/- SEM), hepatic blood flow (-35%) (1.33 +/- 0.2 to 0.87 +/- 0.1 l/min), and renal blood flow (-16%) (0.77 +/- 0.07 to 0.65 +/- 0.05 l/min). Adding nitroprusside restored cardiac output, preload and afterload, and renal blood flow to pretreatment values. Oxygen delivery remained depressed (-12%) because of a negative effect on pulmonary gas exchange (physiologic shunt increased from 16 +/- 2 to 28 +/- 4%). Portal pressures remained reduced by 31% and hepatic blood flow by 25%. These results suggest that small doses of I.V. nitroprusside minimize the deleterious hemodynamic effects of vasopressin while maintaining the therapeutic benefit of portal pressure reduction in cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6696534      PMCID: PMC1353329          DOI: 10.1097/00000658-198402000-00008

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  30 in total

1.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

2.  The use of surgical pituitrin in the control of esophageal varix bleeding; an experimental study and report of two cases.

Authors:  J H KEHNE; F A HUGHES; M L GOMPERTZ
Journal:  Surgery       Date:  1956-06       Impact factor: 3.982

3.  Certain cardiovascular effects of vasopressin (Pitressin).

Authors:  K G WAKIM; C DENTON; H E ESSEX
Journal:  Am Heart J       Date:  1954-01       Impact factor: 4.749

4.  Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (octapressin) in man.

Authors:  J N Cohn; F E Tristani; I M Khatri
Journal:  Circulation       Date:  1968-07       Impact factor: 29.690

Review 5.  Measurement of portal pressure and its clinical application.

Authors:  T B Reynolds; S Ito; S Iwatsuki
Journal:  Am J Med       Date:  1970-11       Impact factor: 4.965

6.  A controlled comparison of continuous intraarterial and intravenous infusions of vasopressin in hemorrhage from esophageal varices.

Authors:  M Chojkier; R J Groszmann; C E Atterbury; S Bar-Meir; A T Blei; J Frankel; M G Glickman; J L Kniaz; R Schade; G J Taggart; H O Conn
Journal:  Gastroenterology       Date:  1979-09       Impact factor: 22.682

7.  Nitroprusside.

Authors:  J N Cohn; L P Burke
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

8.  Nitroprusside prevents adverse hemodynamic effects of vasopressin.

Authors:  S Gelman; E A Ernst
Journal:  Arch Surg       Date:  1978-12

9.  Hypoxic pulmonary vasoconstriction in liver cirrhosis.

Authors:  R Naeije; R Hallemans; P Mols; C Melot
Journal:  Chest       Date:  1981-11       Impact factor: 9.410

10.  Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension.

Authors:  R J Groszmann; D Kravetz; J Bosch; M Glickman; J Bruix; J Bredfeldt; H O Conn; J Rodes; E H Storer
Journal:  Hepatology       Date:  1982 Nov-Dec       Impact factor: 17.425

View more
  8 in total

Review 1.  The management of an episode of variceal bleeding.

Authors:  A E Gimson; D Westaby
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

Review 2.  The management of active variceal bleeding.

Authors:  D Westaby
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

Review 3.  The use of vasopressin in the treatment of upper gastrointestinal haemorrhage.

Authors:  D L Stump; T C Hardin
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

4.  Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver.

Authors:  J Reichen; M Le
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

5.  Hemodynamic effects of combined treatment with somatostatin analogue (SMS 201-995) and low-dose isosorbide dinitrate on portal hypertension in conscious cirrhotic rats.

Authors:  N Hori; T Okanoue; Y Sawa; Y Itoh; T Mori; S Takami; K Kashima
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

Review 6.  Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.

Authors:  Laura C Price; Stephen J Wort; Simon J Finney; Philip S Marino; Stephen J Brett
Journal:  Crit Care       Date:  2010-09-21       Impact factor: 9.097

Review 7.  Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure.

Authors:  Angel Coz Yataco; Melina Aguinaga Meza; Ketan P Buch; Margaret A Disselkamp
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 8.  Pulmonary Hypertension in Intensive Care Units: An Updated Review.

Authors:  Armin Nowroozpoor; Majid Malekmohammad; Seyyed Reza Seyyedi; Seyed Mohammadreza Hashemian
Journal:  Tanaffos       Date:  2019-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.